Skip to main content

Table 2 Therapeutic responses of 27 RRMM patients to single-agent circularly permuted TRAIL (CPT) treatment

From: Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

Responsea

No. of patients (%)

Near-complete response (nCR)

1 (3.7)

Partial response (PR)

8 (29.6)

Minimal response (MR)

4 (14.8)

No change (NC)

3 (11.1)

Progressive disease (PD)

11 (40.7)

ORR (nCR + PR)

9 (33.3)

CBR (nCR + PR + MR)

13 (48.1)

  1. ORR overall response rate, CBR clinical benefit rate, TRAIL tumor necrosis factor-related apoptosis-inducing ligand
  2. aResponses were assessed according to the European Group for Blood and Marrow Transplantation criteria
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us